Key facts
- Genomic Expression’s last known valuation is $25.5M (Oct 2025).
- It has raised $2.3M; the latest was Later Stage VC ($500K) in Oct 2025.
- Notable investors include MedTech Innovator, Springboard Enterprises, Accelerator for Biosciences in Connecticut, Al Sparks, Centurion Holdings — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Genomic Expression
- ·The full record, as it builds
Funding rounds
No funding rounds for Genomic Expression are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genomic Expression
Operator of an RNA diagnostic company intended to detect disease, monitor health, and design cures. The company's platform performs comprehensive analysis of RNA expression using sequencing, AI-driven interpretation, clinical data integration, validation pipelines and bioinformatics tools to identify disease signatures, therapeutic options and individualized profiles from patient samples, enabling healthcare providers, clinical researchers and biotech organizations to detect disease, support personalised treatment decisions, explore repurposing of approved drugs and advance development of next-generation therapies with data-driven insights across oncology and related biomedical applications.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2009
- Employees
- 10
- Website
- genomicexpression.com/
- Ownership
- Privately Held (backing)
Genomic Expression doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genomic Expression shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genomic Expression in its N-PORT filings yet. We sweep new filings monthly.